Immunome, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Immunome, Inc. (IMNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $4.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-11
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $3.60M, a 3500.00% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $500.00K, a 76.19% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $100.00K, a 95.45% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $300.00K, a 86.36% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $2.60M, a 74.76% decline from fiscal 2024.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $10.30M, a 74.58% increase from fiscal 2023.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $5.90M, a 2850.00% increase from fiscal 2022.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $200.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.10M 10-Q · filed 2026-08-11 | $4.20M derived: sum of 3 quarters · filed 2026-08-11 | $4.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-12 | $600.00K derived: sum of 2 quarters · filed 2026-05-12 | $900.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $400.00K derived: sum of 2 quarters · filed 2026-03-03 | $500.00K derived: sum of 3 quarters · filed 2026-08-11 | $2.60M 10-K · filed 2026-03-03 |
| 2025-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $400.00K derived: sum of 2 quarters · filed 2026-08-11 | $2.50M 10-Q · filed 2025-11-06 | $4.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.20M 10-Q · filed 2026-08-11 | $4.40M derived: sum of 3 quarters · filed 2026-08-11 | $6.60M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.10M 10-Q · filed 2026-05-12 | $4.30M derived: sum of 2 quarters · filed 2026-05-12 | $6.50M derived: sum of 3 quarters · filed 2026-05-12 | $9.90M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.40M derived: sum of 2 quarters · filed 2026-03-03 | $7.80M derived: sum of 3 quarters · filed 2026-03-03 | $10.30M 10-K · filed 2026-03-03 |
| 2024-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.60M derived: sum of 2 quarters · filed 2025-11-06 | $8.10M 10-Q · filed 2025-11-06 | $13.90M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.90M 10-Q · filed 2025-08-06 | $11.70M derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | $2.50M 10-Q · filed 2025-05-12 | $8.30M derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $5.90M 10-K · filed 2025-03-19 | ||
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-13 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | $100.00K derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $200.00K 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |